Payment overview · 2025
General Payments
$910.09
60 reported records · 15 companies
Healthcare provider profile · identity verified
Henry Le, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · YUKON, OK · NPI 1417334426
Verified facts
What the public records show
CMS Open Payments records show Henry Le, M.D. received $910.09 in general payments during 2025 across 60 reported records.
PFIZER INC. accounted for 26.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 25 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $243.69 | 26.8% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $141.69 | 15.6% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $96.75 | 10.6% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $62.75 | 6.9% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $60.20 | 6.6% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $48.39 | 5.3% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $46.00 | 5.0% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.40 | 4.9% | 3 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $43.27 | 4.8% | 2 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $38.63 | 4.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.95 | 3.3% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $18.87 | 2.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.08 | 1.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.34 | 1.6% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $6.08 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $910.09 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $133.61 | 9 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $133.61 | 9 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $133.61 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $98.53 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $98.53 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $96.75 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $89.82 | 8 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $62.75 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $62.75 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $60.20 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $51.87 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $48.39 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $46.00 | 3 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $43.27 | 2 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $38.63 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $30.40 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $29.95 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.86 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $18.87 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $15.08 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.27 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.00 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $11.55 | 3 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $6.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 67 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 51 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 99 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 74 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
51 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
99 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
42 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
74 | 17 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
67 | 14 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 613 | 194 |
| Lisinopril | Lisinopril | 314 | 96 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 83 |
| Omeprazole | Omeprazole | 293 | 89 |
| Gabapentin | Gabapentin | 290 | 96 |
| Losartan Potassium | Losartan Potassium | 221 | 68 |
| Metformin Hcl | Metformin Hcl | 219 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 191 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 181 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 166 | 53 |
| Alprazolam | Alprazolam | 151 | 34 |
| Furosemide | Furosemide | 150 | 54 |
| Tramadol Hcl | Tramadol Hcl | 148 | 36 |
| Trazodone Hcl | Trazodone Hcl | 141 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 139 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 37 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 131 | 39 |
| Duloxetine Hcl | Duloxetine Hcl | 125 | 34 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 114 | 38 |
| Glipizide | Glipizide | 110 | 30 |
| Potassium Chloride | Potassium Chloride | 108 | 37 |
| Metoprolol Tartrate | Metoprolol Tartrate | 105 | 24 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 104 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 100 | 29 |
| Mounjaro | Tirzepatide | 99 | 24 |
| Fluoxetine Hcl | Fluoxetine Hcl | 98 | 33 |
| Carvedilol | Carvedilol | 92 | 31 |
| Simvastatin | Simvastatin | 85 | 24 |
| Sertraline Hcl | Sertraline Hcl | 81 | 21 |
| Zolpidem Tartrate | Zolpidem Tartrate | 80 | 16 |
| Allopurinol | Allopurinol | 75 | 24 |
| Ozempic | Semaglutide | 74 | 17 |
| Warfarin Sodium | Warfarin Sodium | 73 | 13 |
| Meloxicam | Meloxicam | 69 | 21 |
| Eliquis | Apixaban | 67 | 14 |
| Propranolol Hcl | Propranolol Hcl | 66 | 18 |
| Alendronate Sodium | Alendronate Sodium | 62 | 21 |
| Pregabalin | Pregabalin | 62 | 17 |
| Montelukast Sodium | Montelukast Sodium | 59 | 26 |
| Famotidine | Famotidine | 58 | 21 |
| Ibuprofen | Ibuprofen | 56 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 56 | 17 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 14 |
| Ropinirole Hcl | Ropinirole Hcl | 56 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 52 | 18 |
| Jardiance | Empagliflozin | 51 | 20 |
| Baclofen | Baclofen | 50 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 50 | 20 |
| Prednisone | Prednisone | 50 | 40 |
| Tizanidine Hcl | Tizanidine Hcl | 48 | 14 |
| Oxybutynin Chloride | Oxybutynin Chloride | 45 | 12 |
| Buspirone Hcl | Buspirone Hcl | 43 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 42 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 42 | 28 |
| Trulicity | Dulaglutide | 42 | 12 |
| Citalopram Hbr | Citalopram Hydrobromide | 41 | 12 |
| Finasteride | Finasteride | 40 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | 12 |
| Bupropion Hcl Sr | Bupropion Hcl | 39 | suppressed |
| Chlorthalidone | Chlorthalidone | 39 | suppressed |
| Nystatin | Nystatin | 39 | suppressed |
| Ondansetron Odt | Ondansetron | 39 | 13 |
| Clonazepam | Clonazepam | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 18 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 36 | 16 |
| Lorazepam | Lorazepam | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Celecoxib | Celecoxib | 33 | 16 |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | 15 |
| Escitalopram Oxalate | Escitalopram Oxalate | 32 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 19 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 31 | 14 |
| Diazepam | Diazepam | 31 | suppressed |
| Azithromycin | Azithromycin | 30 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | suppressed |
| Estradiol | Estradiol | 27 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 24 |
| Armour Thyroid | Thyroid,pork | 25 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 25 | 12 |
| Sucralfate | Sucralfate | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 24 | suppressed |
| Torsemide | Torsemide | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Atenolol | Atenolol | 22 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 20 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Irbesartan | Irbesartan | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Naproxen | Naproxen | 19 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 19 | 16 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 13 |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 18 | suppressed |
| Levetiracetam | Levetiracetam | 18 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 15 | suppressed |
| Colchicine | Colchicine | 14 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 11 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $910.09 · 60 records | PFIZER INC. | ABRYSVO, CAPLYTA, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, QULIPTA, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error